SUBSCRIBE
SUBSCRIBE
News   Deals

Astellas Pharma Inc. Says Bid for CV Therapeutics, Inc. Its Best Offer

February 2, 2009 | 
1 min read
TOKYO, Feb 2 (Reuters) - Japanese drugmaker Astellas Pharma Inc said its $1 billion bid for U.S. biotechnology firm CV Therapeutics Inc is its best offer, ruling out the possibility of sweetening its bid for now.
Mergers & acquisitions Asia
Astellas Pharma US, Inc.
MORE ON THIS TOPIC
Blank paper notes attached by adhesive tape, white background, vector eps10 illustration
Deals
Ipsen sends clear Memo to rare diseases with up to $796M buyout
July 1, 2026
 · 
2 min read
 · 
Gabrielle Masson
Podcast
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
July 1, 2026
 · 
2 min read
 · 
Jef Akst
Upward arrow on the background of the flag of China. Paper plane. Economic recovery. Copy space. Business. Background.
China
Deerfield bets up to $1.6B to snag autoimmune asset in China for Boulevard
June 30, 2026
 · 
1 min read
 · 
Annalee Armstrong
Solution Concept with Handshake on Chalkboard Background
Mergers & acquisitions
Zymeworks adds lung disease drug, royalty deals in nearly $1B pick up of Theravance
June 29, 2026
 · 
2 min read
 · 
Annalee Armstrong